- ORCID: 0000-0001-6310-3486
- Researcher ID: N-3207-2014
- Scopus: 6505865912
- Google Scholar: CHERA
- Research Gate: CHERA
Professor at the Faculty of Medicine, University of Bergen, Norway
2020 – 2021 Invited Professor – Division of Endocrinology, Diabetes, Hypertension and Nutrition; Department of Cell Physiology and Metabolism; Faculty of Medicine, University of Geneva hosted by Prof. Charna Dibner
2015 – Associate Investigator to the Center of Molecular Medicine (NCMM), University of Oslo, Norway (re-appointed in 2020)
2016 – 2020 Førsteamanuensis (Associate Professor) Faculty of Medicine, University of Bergen, Norway
2015 – 2016 Postdoctoral work – Dept. of Clinical Science, University of Bergen at the laboratory of Prof. Helge Raeder
2008 – 2015 Postdoctoral work – Faculty of Medicine, University of Geneva, Switzerland; Advisor: Prof. Pedro Herrera – More details here: https://chera.w.uib.no/about-sim-chera/postdoctoral-studies-cellular-and-molecular-mechanisms-of-regeneration-in-pancreas/
2002 – 2008 PhD work – Faculty of Science, University of Geneva, Switzerland; Advisor: Prof. Brigitte Galliot – More details here: https://chera.w.uib.no/about-sim-chera/phd-studies-cellular-and-molecular-mechanisms-of-regeneration-in-hydra/
|Agency logo||Period||Grant Description|
|2022-2027||Mohn Research Center for Diabetes Precision Medicine (PRECISE-DIA)
Project leader in Work Package 2. The goal of this Research Center is to study the causes of diabetes development over the course of a lifetime.
|2021-2026||Dissecting the role of islet non-ß populations’ identity maintenance in the development of monogenic diabetes
The goal of the project is to combine genetic cell tracing, omics, advanced imaging and physiology to study the islet cell interconversion events upon stress.
|2021-2026||Ascending Investigator Grant
Regulating glucose tolerance by targeting delta-cell population, a freshly uncovered critical player in the pathogenesis of monogenic diabetes
The goal of the project is to combine genetic cell tracing, omics, advanced imaging and physiology to elucidate the cellular and molecular mechanisms involved in monogenic diabetes.
|2021-2022||A novel strategy for improving the insulin-secreting β-cell phenotypical stability
The goal of the project is to improve human β-cell phenotype stability during in vitro differentiation, thus generating correctly matured β-cells much more adequate for clinics.
|2020-2024||Supportive therapy for diabetes by increasing the stress endurance and regenerative capacity of beta-cells
Partnership with Dr. Ana Vacaru (Institute of Cellular Biology and Pathology “Nicolae Simionescu”, Bucharest, Romania) aiming at developing strategies to help the β-cells’ secretory performance i.e. improving their capacity to cope with the increased load in the ER.
|2020||Single Cell Analysis of stressed pancreatic islets
The goal of this project is to study at single cell level the pancreatic islet populations expressing a truncated form of the HNF1A.
|2019-2021||Regulating cell-differentiation potential through mechanical forces and adhesion
A joint application with Dr. Irep Gözen (NCMM, University of Oslo) aiming to study the impact of different mechanical forces and adhesion on islet cell differentiation potential (seed funding).
|2016-2021||FRIPRO Young Research Talent
Characterising and modulating the insulin-producing beta-cell fate in monogenic diabetes by using novel genetic setups
The goal of the project is to combine genetic cell tracing, omics, advanced imaging and physiology to elucidate the cellular and molecular mechanisms involved in diabetes onset.
|2015-2020||Excellence Project for Young Investigators
Characterising and reversing β-cell senescence and proliferation quiescence in monogenic diabetes
The goal of the project is to generate 2 novel transgenic models in order to elucidate and reverse the molecular age-switch controlling the homeostatic gradual decay and proliferation quiescence of β-cells in a form of monogenic diabetes (MODY3).
|2015-2019||STAMCELLER Young Research Talent
Identifying the molecular mechanisms leading to age-related chronic disease onset using an innovative in vivo setup
The goal of the project is to combine omics, complex transgenics, advanced imaging and image analysis to elucidate the cellular and molecular mechanisms involved in diabetes onset by using a novel in vivo strategy based on induced pluripotent stem cells (iPSCs) derived from monogenic diabetes patients (Maturity Onset Diabetes of the Young: MODY1 and MODY3).